Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010262.pdf
0001415889-23-010262.rtf
0001415889-23-010262.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010264.pdf
0001415889-23-010264.rtf
0001415889-23-010264.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-009402.pdf
0001415889-23-009402.rtf
0001415889-23-009402.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-009403.pdf
0001415889-23-009403.rtf
0001415889-23-009403.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-064663.pdf
0001104659-23-064663.rtf
0001104659-23-064663.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-063202.pdf
0001104659-23-063202.rtf
0001104659-23-063202.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
ARS/A

ARS/A

 View HTML
0001104659-23-058510.pdf
0001104659-23-058510.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-055774.pdf
0001104659-23-055774.rtf
0001104659-23-055774.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-23-008120.pdf
0001558370-23-008120.rtf
0001558370-23-008120.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
ARS

An annual report to security holders

 View HTML
0001104659-23-053220.pdf
0001104659-23-053220.rtf